House FDA reform hearing to hear testimony from Centocor CEO Holveck, Amgen's Binder.
CENTOCOR CEO DAVID HOLVECK TO TESTIFY AT APRIL 23 PDUFA/FDA REFORM HEARING of the House Commerce Committee's Subcommittee on Health & Environment. The Biotechnology Industry Organization asked Subcommittee Chairman Bilirakis (R-Fla.) to invite a witness representing small biotechnology manufacturers to testify about the impact of FDA regulation and the approval process on companies with limited resources.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth